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Abstract 
Plasma cell myeloma (PCM) is a complex and 
genetically heterogenous hematological malignancy 
involving clonal proliferation of plasma cells in bone 
marrow.  It is the third most common 
hematolymphoid malignancy in the United States 
and primarily affects elderly people with a median 
onset age of 69 years and a survival duration ranging 
from a few months to more than 10 years. Standard 
karyotype and fluorescence in situ hybridization 
(FISH) evaluation of bone marrow is required in the 
initial diagnostic workup to risk stratify patients 
based on their cytogenetic status.  Primary 
cytogenetic events are classified as either 
hyperdiploid or non-hyperdiploid. Common in non-
hyperdiploid cases is rearrangement of the IGH gene 
on chromosome 14q32.33, most commonly with the 
CCND1 gene at 11q13.3, and to a lesser extent 
FGFR3/MMSET genes at 4p16.3 or the MAF gene 
at 16q23.2.  The rarest of these IGH translocations 
involves the MAFB gene at 20q12, which is the 
subject of this review. 
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Clinics and pathology 
Disease 
Can be found in plasma cell myeloma, monoclonal 
gammopathy of undetermined significance 
(MGUS), smoldering myeloma, plasma cell 
leukemia, and plasmacytoma.  
Collectively, the term plasma cell neoplasms include 
a number of disorders characterized by monoclonal 
gammopathy. The most common of these disorders, 
monoclonal gammopathy of undetermined 
significance (MGUS), is characterized by the 
infiltration of clonal plasma cells into bone marrow 
(10% plasma cells on bone marrow biopsy, but 
without CRAB criteria.  The risk for progression to 
PCM is higher, with 10% per year progressing to 
PCM in the first five years. 3% per year for the next 
5 years, and 1% per year for the subsequent 10 years 
[Kumar et al, 2017, Cosemans et al, 2018].  
A diagnosis of plasma cell myeloma requires 
detection of a monoclonal protein by serum protein 
electrophoresis (SPEP), urine protein 
electrophoresis (UPEP), or by pathological serum 
free light chain (sFLC) ratio along with a plasma cell 
count ≥ 10%.  The development of end-organ 
damage is the indication for treatment.  Other 
possible pathological presentations of a plasma cell 
neoplasm include a non-secretory myeloma which 
requires >30% plasma cells, a non-systemic solitary 
plasmacytoma, or plasma cell leukemia with a 
peripheral blood plasmacytosis >20% [Rollig et al, 
2015]. 
Phenotype/cell stem origin 
Post-germinal center, terminally differentiated 
plasma cell.  
Plasma cells develop from hematopoietic stem cells 
that differentiate first into B-cells, then eventually 
after several rounds of differentiation into plasma 
cells. The final differentiation stage of B-cells occurs 
in bone marrow and involves rearrangement of the 
immunoglobulin heavy chain gene (IGH), followed 
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by rearrangement of the light chain genes [IG kappa 
(IGK) and IG lambda [IGL)].  The mature B cell than 
exits the bone marrow to populate secondary 
lymphoid organs where it will continue its 
maturation.  Somatic hypermutation occurs within 
the germinal centers of these secondary lymphoid 
organs, involving stochastic mutations within the 
VDJ segment.  The final maturation stage involves 
class switch recombination, resulting in the mature 
B-cell expressing IgG, IgA, or IgE.  The mature B-
cell will now either differentiate into a memory B-
cell or return to bone marrow as a long-lived plasma 
cell [Corre et al, 2015]. 
Etiology 
The cause of PCM is unknown, but potential 
environmental and occupational risk factors have 
been proposed.  In addition, genetic risk factors have 
been elucidated through genome-wide association 
studies (GWAS) which have identified multiple 
susceptibility loci, as well as loci associated with 
inferior survival and with development of drug-
induced toxicity (such as bortezomib-induced 
neuropathy) [Kumar et al, 2017]. 
Epidemiology 
PCM accounts for approximately 1.8% of all cancers 
and a little more than 17% of all hematologic 
malignancies in the United States.  According to the 
American Cancer Society, an estimated 30,280 new 
cases will be diagnosed in the United States in 2017, 
with an estimated 12,590 deaths.  The incidence of 
PCM is 2-3 times higher in African-American 
individuals compared with Caucasians.  The 
prevalence has increased, likely because of better 
diagnostic techniques and increased survival as the 
result of novel therapeutic agents and autologous 
stem cell transplantation [Kumar et al, 2017].  
Approximately 40-50% of myeloma cases 
demonstrate an IGH gene rearrangement.  The 
t(14;20)(q32;q12) is the rarest of the five most 
common IGH-rearrangements, found in 
approximately 1% of cases [Manier et al, 2016]. 
Pathology 
After developing a primary genetic abnormality, 
either hyperdiploidy or an IGH gene rearrangement, 
plasma cells induce stromal cells to produce 
numerous cytokines, especially interleukin-6. 
Plasma cells undergo additional genetic alterations 
that prevent normal cell differentiation and 
apoptosis.  The end result is the immortalization of a 
plasma cell clone. Recent DNA sequencing studies 
have identified two types of clonal evolution in 
plasma cell myeloma.  Genetic heterogeneity 
appears to be acquired either through linear 
evolution with acquisition of secondary mutations 
over time in the original clone or through branching 
evolution, whereby multiple subclones diverge to 
produce greater genetic heterogeneity.  Such 
subclones, it is theorized, coexist and compete for 
space and stromal support within the bone marrow 
microenvironment. The kinetics of this evolution has 
important implications for therapy [Coore et al, 
2015; Pawlin et al, 2015].  
Malignant plasma cells are positive by flow 
cytometry for CD138 and CD38, negative for CD19, 
and either positive or negative for CD45 and CD56.  
Immunohistochemical detection of CD138 
(syndecan-1) helps to quantify plasma cell in tissue. 
Detection of CD56, cyclin-D1, and CD117 are also 
helpful. 
Prognosis 
Plasma cell myeloma cases with a t(14;20)(q32;q12) 
have a poorer prognosis; however, paradoxically, 
identification of the translocation in MGUS or SM 
may be associated with long-term stable disease 
[Ross FM et al, 2010]. This suggests that additional 
molecular events are necessary in those cases that 
progress to plasma cell myeloma, and that those 
secondary molecular events specifically associated 
with the rearrangement may be the factors actually 
responsible for the negative prognosis. A recent 
study demonstrated that cases of MGUS or SM that 
progress to overt myeloma do so through acquisition 
of mutations in APOBEC (apolipoprotein B mRNA 
editing catalytic polypeptide-like) cytidine 
deaminases [Bolli N et al, 2018]. Some myeloma 
patients are found to have coexistent hyperdiploidy 
(a good prognostic marker) as well as a high-risk 
IGH rearrangement such as the t(14;20).  Single cell 
analysis reveals that hyperdiploidy may precede IGH 
translocation.  In such cases, coexistent 
hyperdiploidy does not change the otherwise poor 




Figure 1. Partial karyotype demonstrating the 
t(14;20)(q32;q12). The normal chromosomes 14 and 20 are 
to the left of the derivative chromosomes. 
Cytogenetics morphological 
The t(14;20)(q32;q12) is the rarest of the five most 
common translocations in myeloma that involve the 
IGH gene.  It is found in about 1% of all myeloma 
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cases, and in the few cases that have been reported, 
the translocation has been balanced.  Unlike the other 
relatively uncommon IGH gene translocations 
t(4;14) and t(14;16) that are often undetectable by 
conventional cytogenetic analysis of bone marrow 
(which yields chromosomes of lower resolution and 
require FISH analysis), the t(14;20) can be observed 
in metaphase chromosome preparations.  However, 
FISH utilizing an IGH/MAFB dual-color, dual-
fusion translocation should still be performed to 
confirm the translocation, even in those cases which 
appear to demonstrate the translocation by 
karyotype. 
 
Figure 2. FISH analysis utilizing a IGH/MAFB dual-color, 
dual-fusion translocation DNA probe reveals IGH/MAFB 
rearrangement (identified by a one red, one green, and two 
fusion signals hybridization pattern) in a patient positive for 
the t(14;20)(q32;q12). 
Genes involved and 
proteins 
IGH (Immunoglobulin Heavy Locus) 
Location 14q32.33 
Protein 
This gene encodes a protein which comprises the 
heavy chain of human immunoglobulins.  
Immunoglobulins recognize foreign antigens and 
initiate immune responses.  Each immunoglobulin 
molecule contains two identical heavy chains and 
two identical light chains. 
MAFB (v-maf Avian 
Musculoaponeurotic Fibrosarcoma 
Oncogene Homologue B) 
Location 20q12 
Protein 
This gene is one of the Maf family of transcription 
factors which includes MAFA, MAFB, MAF, and 
NRL (neural retina-specific leucine zipper).  It 
consists of a single exon and codes for a protein 
which is a basic leucine zipper (bZIP) transcription 
factor that can act as either a transcriptional activator 
or repressor.  It plays an important role in the 
regulation of lineage-specific hematopoiesis as well 
as in development. 




The t(14;20)(q32;q12) results in upregulation of 
expression of the MAF paralogue MAFB.  Gene 
expression studies have revealed that MAFB 
overexpression produces an expression profile 
similar to that observed in MAF overexpression, 
suggesting similar downstream targets [Zhan et al, 
2006].  Using an inducible system to upregulate 
MAFB in multiple myeloma cell lines, fourteen 
upregulated genes were identified, including 
CCND1, CCND2, and NOTCH2.  The same 
upregulated genes are, in fact, targets of the entire 
MAF group of transcription factors, suggesting 
similar pathogenic molecular mechanisms in both 
MAF and MAFB dysregulated myelomas [van 
Stralen et al, 2009].  
Myeloma cases with either of the two poor prognosis 
translocations, t(14;16) (q32;q23) and 
t(14;20)(q32;q12) associated with MAF or MAFB 
gene dysregulation, respectively, have been shown 
to have a higher mutational burden than other 
cytogenetic groups of myeloma and to have an 
APOBEC gene signature resulting in overexpression 
of APOBEC3Aand APOBEC3B genes. ENCODE 
data demonstrates a maf transcription factor binding 
site in the promoter regions of both genes, providing 
the link between MAF or MAFB dysregulation and 
increased tumor load [Walker BA et al, 2015].  The 
t(14;16) and t(14;20) are known to be associated 
with long-term stable disease in MGUS and SM 
despite their poor prognostic indication in plasma 
cell myeloma.  This raised the possibility that the 
APOBEC signature is acquired at a later stage in the 
disease, and only at that time does the condition 
transform to plasma cell myeloma. A very recent 
study has proven that APOBEC activity does, in fact, 
increase with disease progression from MGUS or 
SM to overt PCM  [Bolli N et al, 2018].  
Finally, genome-scale methylation profiling studies 
have shown that the MAFB protein establishes an 
epigenetic program in hematopoietic 
stem/progenitor cells which can reset the genome of 
such cells to a terminally differentiated tumor state 
[Vicente-Dueñas et al, 2012]. 
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